Search

CN-122017254-A - Application of Abeta 1-42 and CD64 combination in preparation of reagent for early detection of sepsis

CN122017254ACN 122017254 ACN122017254 ACN 122017254ACN-122017254-A

Abstract

The invention provides an application of Abeta 1-42 and CD64 in the preparation of a reagent for early detection of sepsis, belongs to the technical field of biology, and has the advantages that the diagnosis value of the combined detection of the Abeta 1-42 and the CD64 is obviously higher than that of a single index, a synergistic effect is generated, and the technical problem of insufficient sensitivity or specificity of a single marker is solved. CD64 responds rapidly, aβ1-42 being closely associated with the pathological process, and this combination helps identify high risk patients early in the disease, competing for valuable intervention time clinically. The marker combination not only can be used for qualitative diagnosis, but also has positive correlation between the quantitative level and the severity of the disease, and can be used for risk stratification and prognosis judgment, and the functions are comprehensive.

Inventors

  • FENG ZHONGXUE

Assignees

  • 四川大学华西医院

Dates

Publication Date
20260512
Application Date
20260212

Claims (5)

  1. Use of a combination of aβ1-42 and CD64 for the preparation of a reagent for early detection of sepsis.
  2. 2. A kit for early detection of sepsis, comprising reagents for detecting aβ1-42 and CD 64.
  3. 3. The kit of claim 2, wherein a patient is indicated to have sepsis when the CD64 index is >3.30, aβ1-42>50 pg/mL.
  4. 4. The kit of claim 3, wherein the sample for detecting sepsis comprises whole blood, serum, or plasma.
  5. 5. The kit of claim 2, wherein the method of detecting aβ1-42 and CD64 comprises a flow fluorescence method or an immunization method.

Description

Application of Abeta 1-42 and CD64 combination in preparation of reagent for early detection of sepsis Technical Field The invention belongs to the technical field of biology, and particularly relates to application of Abeta 1-42 and CD64 in preparation of a reagent for early detection of sepsis. Background Sepsis (Sepsis) is a systemic inflammatory response syndrome caused by infection that can further progress to severe sepsis, septic shock, and multiple organ dysfunction syndrome. The pathological mechanism of the disease is complex, and the core is that the reaction of the organism to infection is out of control, which leads to extensive activation of immune and coagulation systems, endothelial injury and organ dysfunction. The clinical manifestations of patients are fever or hypothermia, increased heart rate, shortness of breath, altered consciousness and the like, the conditions are often progressive aggravated, and life-threatening complications such as acute kidney injury, acute respiratory distress syndrome, circulatory failure and the like rapidly occur. Sepsis has become one of the leading causes of death in intensive care units due to its hidden onset, rapid progression, high mortality rate. At present, early diagnosis and intervention of sepsis is critical to improve prognosis, but clinical practice still faces serious challenges. There is no marker currently available for direct early diagnosis of sepsis. PCT and CRP are two most commonly used markers for clinically judging infection, but the detection value is generally only used for judging the intensity of the evidence of infection, and is difficult to directly diagnose sepsis. In recent years, a large number of new markers have been reported in papers, but most of the markers are not yet directly applied to clinic. PCT and CRP have limitations in early sensitivity, specificity in that PCT may not rise significantly in non-bacterial, local or inflammatory states, CRP has a relatively late response and is affected by a variety of non-infective factors. In addition, sepsis is strong in heterogeneity, and different pathogens, infection sites and host immune states lead to complex and variable biomarker expression profiles, so that accurate early identification, risk stratification and prognosis evaluation are difficult to achieve by a single index. Therefore, the novel and efficient biomarker or combination which can reflect the specific pathophysiology links of sepsis and has the cooperative diagnosis value is needed to be discovered in the field, so that the bottleneck of the existing diagnosis technology in the aspects of early stage and accuracy is broken through, and a more reliable basis is provided for clinical timely intervention and personalized management. Disclosure of Invention In view of the above, it is an object of the present invention to provide the use of a combination of aβ1-42 and CD64 for the preparation of a reagent for early detection of sepsis. In order to achieve the above object, the present invention provides the following technical solutions: The invention provides an application of Abeta 1-42 and CD64 in combination in preparing a reagent for early detection of sepsis. The invention provides a kit for early detection of sepsis, which comprises reagents for detecting Abeta 1-42 and CD 64. Preferably, sepsis is indicated when the CD64 index is >3.30, aβ1-42>50 pg/mL. Preferably, the sample for detecting sepsis comprises whole blood, serum or plasma. Preferably, the method for detecting Abeta 1-42 and CD64 comprises a flow fluorescence method or an immunization method. Compared with the prior art, the invention has the following beneficial effects: The invention combines CD64 and Abeta 1-42 for sepsis diagnosis for the first time. Through creative combination of two markers which play different roles in the pathophysiology process of sepsis and have different dynamics characteristics, the ultra-early and high-precision early warning of sepsis is realized, and the core bottleneck that the sensitivity and the specificity of the existing diagnosis technology cannot be achieved in the disease window period is effectively solved. Experiments prove that the diagnosis value (AUC) of the combined detection of the two is obviously higher than that of a single index, a synergistic effect is generated, and the technical problem of insufficient sensitivity or specificity of a single marker is solved. CD64 responds rapidly, aβ1-42 being closely associated with the pathological process, and this combination helps identify high risk patients early in the disease, competing for valuable intervention time clinically. The marker combination not only can be used for qualitative diagnosis, but also has positive correlation between the quantitative level and the severity of the disease, and can be used for risk stratification and prognosis judgment, and the functions are comprehensive. Drawings FIG. 1 is a graph of ROC results for CD 64;